Our Blog

Immutep (ASX:IMM) global leader in development of LAG 3 Gene immuno-therapies

24 Jun 2020 – Immutep (ASX:IMM) CEO, Marc Voigt provides an update on its clinical trials including metastatic breast cancer (MBC), its global leadership under Chief Scientist and Medical Officer, Professor Frederic Triebel, and the growing interest by big pharma in immuno-therapies.


Source: Finance News Network

Share this post